7 news items
FibroGen Shares Climb On Strong Q1 Sales
FGEN
7 May 24
data on FG-3246, our CD46 targeted antibody drug conjugate, in metastatic castration-resistant prostate cancer and continued robust growth of our
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
ADTN
AMBC
AORT
7 May 24
Yigal Nochomovitz initiated coverage on Summit Therapeutics with a Buy rating and announced a price target of $7.
Hims & Hers
FibroGen Reports First Quarter 2024 Financial Results
FGEN
6 May 24
Reported compelling data from Phase 1 monotherapy study of FG-3246, a CD46 targeted antibody drug conjugate
FibroGen to Report First Quarter 2024 Financial Results
FGEN
29 Apr 24
been accepted for review by the China Health Authority. FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN
24 Apr 24
-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant
wltb42zeh4clj5kz72war406dpcocxpx4cdek6ri39
ABAT
ABIO
ACORQ
3 Apr 24
to Buy and announced a $6 price target.
Dave & Buster's Entertainment, Inc
rrmlnwsvoruf ysh48aalk
FGEN
2 Apr 24
of 1.2 mg/kg and higher is quite favorable and highlights the therapeutic potential of FG-3246 as a new ADC aimed at a novel target. These findings
- Prev
- 1
- Next